tbuckley/cabot-search huggingface dataset:
Effect of Adeno-Associated Virus on Cancer Expression by Herpesvirus-Transformed Hamster Cells 2
Authors: George Cukor, Neil R. Blacklow, Kibrick Sidney, Ingrid C. Swan
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Effect of Adeno-Associated Virus on Cancer Expression by Herpesvirus-Transformed Hamster Cells Get access George Cukor, George Cukor Search for other works by this author on: Oxford Academic PubMed Google Scholar Neil R. Blacklow, Neil R. Blacklow Search for other works by this author on: Oxford Academic PubMed Google Scholar Kibrick Sidney, Kibrick Sidney Search for other works by this author on: Oxford Academic PubMed Google Scholar Ingrid C. Swan Ingrid C. Swan Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 55, Issue 4, October 1975, Pages 957–959, https://doi.org/10.1093/jnci/55.4.957 Published: 01 October 1975 Article history Received: 14 March 1975 Accepted: 03 June 1975 Published: 01 October 1975
Dishonesty in scientific research
Authors: Nina Mazar, Dan Ariely
Journal: Journal of Clinical Investigation (2015)

Fraudulent business practices, such as those leading to the Enron scandal and the conviction of Bernard Madoff, evoke a strong sense of public outrage. But fraudulent or dishonest actions are not exclusive to the realm of big corporations or to evil individuals without consciences. Dishonest actions are all too prevalent in everyone's daily lives, because people are constantly encountering situations in which they can gain advantages by cutting corners. Whether it's adding a few dollars in value to the stolen items reported on an insurance claim form or dropping outlier data points from a figure to make a paper sound more interesting, dishonesty is part of the human condition. Here, we explore how people rationalize dishonesty, the implications for scientific research, and what can be done to foster a culture of research integrity.
Pathogenesis of antibody‐induced acquired von willebrand syndrome
Authors: Tong Eng Gan, Ronald J. Sawers, Jerry Koutts
Journal: American Journal of Hematology (1980)

A patient with clinical and laboratory evidence of von Willebrand syndrome is described in association with an IgG-kappa immunoglobulin and Bence-Jones proteinuria due to a probable lymphoproliferative disorder. He had a persistently prolonged bleeding time of greater than 20 minutes, factor VIII related antigen (VIII:R.Ag), factor VIII procoagulant activity (VIII:C) and factor VIII ristocetin co-factor (VIIIR:Rcof) below 10%. Following cryoprecipitate or high purity factor VIII concentrate infusion, he had the expected immediate rise in VIII:C, VIII:R.Ag, and VIIIR:Rcof, but there was a rapid decline in all three components within two hours. The larger forms of VIII:R.Ag were preferentially removed from the plasma, and this paralleled the fall in plasma VIIIR:Rcof level. However, no inhibitory activity could be demonstrated in vitro using the patient's plasma or IgG. Using protein A it was possible to demonstrate that his plasma or IgG bound factor VIII and that this complex retained its biological activity in vitro. It is postulated that the monoclonal IgG forms complexes with factor VIII in vivo and these are rapidly removed by the reticuloendothelial system (RES).
Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities
Authors: Baris Akinci, Fatos Dilan Koseoglu, Huseyin Onay, Sevgi Yavuz, Canan Altay, Ilgin Yildirim Simsir, Secil Ozisik, Leyla Demir, Meltem Korkut, Nusret Yilmaz, Samim Ozen, Gulcin Akinci, Tahir Atik, Mehmet Calan, Mustafa Secil, Abdurrahman Comlekci, Tevfik Demir
Journal: Metabolism (2015)
MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice
Authors: Yongxia Wu, Jessica Heinrichs, David Bastian, Jianing Fu, Hung Nguyen, Steven Schutt, Yuejun Liu, Junfei Jin, Chen Liu, Qi-Jing Li, Changqing Xia, Xue-Zhong Yu
Journal: Blood (2015)
In vitro expansion of CMV-specific CD4+ T-cells by artificial antigen presentation for adoptive immunotherapy in the post- transplant setting
Authors: R. J. Ricafort, M. Stephan, R. O’Reilly, M. Sadelain
Journal: Journal of Clinical Oncology (2007)

3049 Background: CMV continues to be a major cause of morbidity and mortality in marrow allograft recipients. The importance of CD4+ T-cells in maintaining immunity and therapeutic efficacy in adoptive cellular strategies has been appreciated. With a novel artificial antigen presenting cell (AAPC) system, we induced the expansion of CMV-specific CD4+ T-cells. Methods: AAPCs were generated by using a standardizable line of murine 3T3 cells sequentially transduced to express human ICAM-1, LFA-1, B7.1, HLA A*0201 and DRB1*1101 alleles. Antigen was provided either by peptide pulsing with the HLA-DRB1*1101-restricted, CMV- pp65-derived P92 peptide, or the influenza matrix peptide (IMP) as a control, or by transgene expression of pp65. PBMCs were isolated from a CMV+, HLA*A02, DRB1*11-positive healthy donor after informed consent, and enriched for T-cells via positive selection using sheep RBCs. Cocultures of T-cells with AAPCs were established at a ratio of 10:1. 20 IU/ml of IL-2 was added on d7 and every third day thereafter. On d12- 14 of co-culture, the T-cells were restimulated on a fresh monolayer of AAPCs with antigen. Cells were counted in triplicate via hemocytometer with trypan blue exclusion. Immunophenotyping of expanded T-cells was done via flow cytometric analysis for cell surface expression of CD3, CD8, CD4, and soluble Class II (HLA-DRB1*1101) tetramer specific for the P92 peptide of CMV-pp65. Results: Following 3 rounds of stimulation, antigen-specific fold expansion, defined by DR11,P92-tetramer-positive, CD4+ T-cells, was 313-fold when stimulated on AAPC.A2.DR11.PP65, compared to 5–35-fold using the other AAPC controls. Conclusion: We are able to expand clinically relevant numbers of CMV-specific CD4+ T-cells using a rapid, practicable, and broadly applicable approach. These preclinical studies show the feasibility of generating virus-specific T-cells of desired specificity and HLA restriction for adoptive immunotherapy of severe CMV infections. [Table: see text] No significant financial relationships to disclose.
Cancer and Cardiac Mortality Among 15-Year Survivors of Cancer Diagnosed During Childhood or Adolescence
Authors: Daniel M. Green, Andrew Hyland, Catherine S. Chung, Michael A. Zevon, Brenda C. Hall
Journal: Journal of Clinical Oncology (1999)

PURPOSE: To evaluate the impact of cardiac disease and second malignant neoplasms on late mortality rate and to identify risk factors for late mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. PATIENTS AND METHODS: Gender-specific all-cause and cause-specific (cardiac disease, cancer) standardized mortality ratios were calculated. Kaplan-Meier survival estimates and Cox regression analyses were performed to determine the relationship of several demographic and treatment variables to survival. RESULTS: Patients who survived for 15 years after diagnosis had excess subsequent all-cause, cancer (second malignant neoplasms only), and cardiac mortality rates. No decrease in the late mortality rate by treatment era (1960 to 1970, 1971 to 1984) was identified. Risk factors for males included disease recurrence during the first 15 years after diagnosis, treatment with doxorubicin, and the diagnosis of Hodgkin's disease. Those for females included treatment with radiation therapy, treatment with an alkylating agent, and disease recurrence during the first 15 years after diagnosis. Cox regression analysis demonstrated that only an initial duration of remission of less than 15 years (P &lt; .01) and treatment with doxorubicin (P = .08) were significantly associated with shorter survival time for males. No variable was significantly associated with shorter survival time for females in Cox regression analysis. CONCLUSION: Fifteen-year survivors of childhood cancer have excess mortality. More effective treatments must be developed to reduce this excess risk. Fifteen-year relapse-free survivors did not have excess mortality. This group will require continued observation to determine whether excess mortality will become apparent as more events occur.
A large increase of Salmonella infections in 2003 in the Netherlands: hot summer or side effect of the avian influenza outbreak?
Authors: W van Pelt, D. J Mevius, H G Stoelhorst, S Kovats, A. W van de Giessen, W J B Wannet, Y T H P Duynhoven
Journal: Eurosurveillance (2004)

In June 2003, the Dutch national Salmonella centre reported a significant excess isolation rate of Salmonella Enteritidis when compared with earlier years in most regional public health laboratories. By the end of 2003, this amounted to an extra 540 laboratory confirmed cases for the whole of the Netherlands, which implies an estimated 7500 extra cases of gastroenteritis caused by S. Enteritidis in the general population, an increase of 50% on previous years. The hot summer could not explain the findings. Strong evidence has been found to suggest that the increase in importation of salmonella contaminated eggs, as a side effect of a concurrent avian influenza outbreak, was the most probable reason for this excess.
Why do we need a classification of urogenital tuberculosis
Authors: Ekaterina Kulchavenya
Journal: European Respiratory Journal (2014)

Introduction.  Urogenital tuberculosis (UGTB) remains an important problem. Classification of the disease includes dispersion on forms and stages and definition for each stage, which implies different approach to the management.   Material and methods.  To estimate the benefit of clinical classification of UGTB (Kulchavenya, 2004) we analyzed history cases of 131 pts with UGTB.   Results.  Among 131 pts in 67.2% the isolated kidney tuberculosis (KTB) was diagnosed, in 25.2% – genital tuberculosis (MGTB); 7.6% men had generalized UGTB (gUGTB), when both urinary and male genital systems were hurted by tuberculosis; all of them had KTB-4. Thus, KTB was diagnosed in 75% (including 8% of gUGTB). In spectrum of KTB more than half cases were destructive forms (levels 3-4). KTB-3 was diagnosed in 22.4%, isolated KTB-4 - in 21.4%. But as 10 men gUGTB also had KTB-4 too, total share of destructive forms got 54.0%. KTB-1 was diagnosed in 10.2%, KTB-2 – in 39.8%. Clinical features and symptoms significantly varied between different forms of UGTB.  KTB 1-2 levels were treated with chemotherapy, KTB-3 required partial nephrectomy, KTB- 4 was indicated for nephrectomy. Stricture of ureter was indicated for reconstructive surgery in KTB 1- 3; KTB-4 with stricture of ureter was indicated for nephrureterectomy. MGTB was treated with chemotherapy; fistula, discharge sinus were indicated for surgery. gUGTB was managed depending on forms of KTB and MGTB.   Conclusion.  Join term “UGTB” has insufficient information in order to estimate therapy, surgery and prognosis – as well as to evaluate the epidemiology as UGTB is multivariant disease. Using clinical classification will improve the efficiency of the therapy of UGTB.
Ia-Restricted Interaction of Normal Lymphoid Cells and SJL Lymphoma (Reticulum Cell Sarcoma) Leading to Lymphokine Production. II. Rapid Production of Antibody-Enhancing Factor, Interleukin 2, and Immune Interferon&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: N M Ponzio, T Hayama, C Nagler, I R Katz, M K Hoffmann, K Gilbert, J Vilcek, G J Thorbecke
Journal: JNCI Journal of the National Cancer Institute (1984)

Mixed cell cultures of syngeneic lymph node (LN), spleen, or thymus and gamma-irradiated, syngeneic lymphoma cells of transplantable reticulum cell sarcomas (gamma-RCS) produced within 24 hours high titers of interleukin 2 (IL-2) and immune interferon in their supernatant (SN). These lymphokine titers were much higher than those seen after stimulation with allogeneic cells. SN also had marked enhancing activity for antibody production by anti-T-cell serum plus complement-treated spleen cells to trinitrophenylated polyacrylamide in vitro. This activity could be removed by absorption with cells of an IL-2-dependent cytotoxic cell line. Mixtures of gamma-RCS and LN cells from SJL/J F1 hybrid mice produced these lymphokines only when the non-SJL parent contributed H-2s or H-2b, but not H-2k or H-2d, in the I-region. These I-region restrictions were similar to those observed previously with respect to the ability of T-cells from SJL F1 hybrids to give proliferative responses to gamma-RCS in vitro and of these mice to support tumor growth in vivo. gamma-RCS also induced rapid interferon production in vivo, but serum titers 24 hours after injection consisted primarily of interferon resistant to pH 2 and neutralized by antibody to virally induced interferon (IFN-alpha/beta), and the production of IFN-alpha/beta was not subject to the same genetic restrictions. Although reticulum cell sarcoma cell extracts had no detectable effect in vitro, they were capable of inducing transient IFN production in vivo.
Exogenous lipoid pneumonia complicated by Mycobacterium fortuitum and Aspergillus fumigatus infections
Authors: I Jouannic, B Desrues, H Lena, ML Quinquenel, PY Donnio, P Delaval
Journal: European Respiratory Journal (1996)

We report the case of a nonimmunocompromised female patient, who developed exogenous lipoid pneumonia with Mycobacterium fortuitum infection at diagnosis, later followed by Aspergillus fumigatus infection. The association of exogenous lipoid pneumonia with atypical mycobacterial infection is uncommon but well-recognized, but, to our knowledge, association with A. fumigatus infection has not previously been reported.
Cisplatin, Doxorubicin, and Delayed Surgery for Childhood Hepatoblastoma: A Successful Approach—Results of the First Prospective Study of the International Society of Pediatric Oncology
Authors: Jon Pritchard, Julia Brown, Elizabeth Shafford, Giorgio Perilongo, Penelope Brock, Claire Dicks-Mireaux, Jean Keeling, Angela Phillips, Anton Vos, Jack Plaschkes
Journal: Journal of Clinical Oncology (2000)

PURPOSE: Hepatoblastoma (HB) is a rare malignant liver tumor which occurs almost exclusively in childhood. In the 1970s, survival was approximately 20% to 30%. Since the introduction of cisplatin (PLA) and doxorubicin (DO) into the chemotherapy regimens used to treat these patients, the survival rate has improved dramatically. In most recent studies, primary surgery preceded chemotherapy. In this study by the liver group of the International Society of Pediatric Oncology the aim was to improve survival and reduce operative morbidity and mortality by using preoperative chemotherapy. PATIENTS AND METHODS: After biopsy and assessment of pretreatment extent of disease all patients were treated with continuous 24-hour intravenous infusion of PLA 80 mg/m 2 followed by DO 60 mg/m 2 over 48 hours (PLADO). After four courses of this chemotherapy, patients were reassessed. Where possible, the primary tumor was resected and treatment completed with two more courses of chemotherapy. RESULTS: One hundred fifty-four patients were registered in the study, and 138 received preoperative chemotherapy. One hundred thirteen (82%) showed a partial response with tumor shrinkage and serial decrease of serum alpha-fetoprotein levels. One hundred fifteen patients had delayed surgery, and 106 (including six with liver transplants) had complete resection of primary tumor. Five-year event-free survival was 66%, and overall survival was 75%. CONCLUSION: This study demonstrates that international collaboration on a large scale is feasible. The toxicity of chemotherapy and morbidity of surgery were acceptable and the overall survival gratifyingly high. We now regard PLADO chemotherapy and delayed surgery to be the best available treatment for children with HB. Other treatment programs should be measured against this standard.
Predictors of Late Asthmatic Response
Authors: PEDRO C. AVILA, MARK R. SEGAL, HOFER H. WONG, HOMER A. BOUSHEY, JOHN V. FAHY
Journal: American Journal of Respiratory and Critical Care Medicine (2000)

To identify predictors of the late asthmatic response (LAR), we reviewed data from 60 asthmatic subjects who had undergone allergen challenge over the past 5 yr (33 females, age 31.4 +/- 6.7 yr [mean +/- SD], FEV(1) 90% +/- 14% predicted). Variables considered likely predictors of LAR included baseline FEV(1), PC(20) methacholine (PC(20)), sputum eosinophil percent, and the decrease in FEV(1) within 20 min of allergen challenge. A LAR (FEV(1) >/= 15% fall between 3 and 7 h after challenge) was documented in 57% of subjects. A variety of logistic regression methods revealed a significant inverse association between LAR and PC(20) (odds ratio [OR] = 0.14 [95% CI = 0.03-0.66]) and a positive association between LAR and the decrease in FEV(1) at 20 min (OR = 1.18 [1.04 -1.33]). Classification tree analysis revealed that a threshold of 0.25 mg/ml for PC(20) was most predictive of LAR; LAR developed in 87% of those with PC(20) </= 0.25 mg/ml (n = 23) and in 38% of those with PC(20) > 0.25 mg/ml (n = 37). Notably, in subjects with PC(20) > 0.25 mg/ml, the incidence of LAR increased from 38% to 57% if the allergen-induced decline in FEV(1) at 20 min was >/= 27%. Surprisingly, baseline FEV(1) and percent eosinophils in induced sputum were not significantly associated with LAR. We conclude that a threshold value of 0.25 mg/ml for PC(20) methacholine is a good predictor of LAR. Measuring the PC(20) methacholine may be useful as a screening method to improve the efficiency of identifying asthmatic subjects with a LAR.
The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
Authors: Akira Yasuda, Hirozumi Sawai, Hiroki Takahashi, Nobuo Ochi, Yoichi Matsuo, Hitoshi Funahashi, Mikinori Sato, Yuji Okada, Hiromitsu Takeyama, Tadao Manabe
Journal: Molecular Cancer (2006)

The transmembrane protein c-kit is a receptor tyrosine kinase (KIT) and KIT is expressed in solid tumors and hematological malignancies such as gastrointestinal stromal tumor (GIST), small-cell lung cancer and chronic myelogenous leukemia (CML). KIT plays a critical role in cell proliferation and differentiation and represents a logical therapeutic target in GIST and CML. In pancreatic cancer, c-kit expression has been observed by immunohistochemical techniques. In this study, we examined the influence of c-kit expression on proliferation and invasion using five pancreatic cancer cell lines. In addition, the inhibitory effect of imatinib mesylate on stem cell factor (SCF)-induced proliferation and invasion was evaluated. Finally, we also analyzed KIT and SCF expression in pancreatic cancer tissues using immunohistochemistry and correlated the results with clinical features. RT-PCR revealed that two pancreatic cancer cell lines, PANC-1 and SW1990, expressed c-kit mRNA. By Western blot analysis, c-kit protein was also present in those lines. In KIT-positive pancreatic cancer cell lines, proliferation and invasion were significantly enhanced by addition of SCF. In contrast, SCF did not enhance proliferation and invasion in the three KIT-negative lines (BxPC-3, Capan-2 and MIA PaCa-2). 5 μM imatinib mesylate significantly inhibited SCF-enhanced proliferation to the same extent compared with the control. Similarly, SCF-enhanced invasive ability was significantly inhibited by 5 μM imatinib mesylate. KIT was expressed in 16 of 42 clinical specimens by immunohistochemistry, and KIT expression was significantly related to venous system invasion. Furthermore, patients expressing both KIT and SCF had a somewhat lower survival. Our results demonstrated that the SCF-KIT pathway enhanced the proliferation and invasiveness in KIT-positive pancreatic cancer cell lines and that the enhanced proliferation and invasion were inhibited by imatinib mesylate. We propose that inhibitors of c-kit tyrosine kinase receptor have the potential to slow the progression of KIT-positive pancreatic cancers.
Prospective Study of the Clinical Course, Prognostic Factors, Causes of Death, and Survival in Patients With Long-Standing Zollinger-Ellison Syndrome
Authors: Fang Yu, David J. Venzon, Jose Serrano, Stephan U. Goebel, John L. Doppman, Fathia Gibril, Robert T. Jensen
Journal: Journal of Clinical Oncology (1999)

The long-term clinical course of unselected patients with gastrinomas as well as other functional pancreatic endocrine tumors (PETs) in whom the excess-hormone state is controlled is largely unknown. To address this issue, patients with gastrinomas were assessed.Two hundred twelve patients with Zollinger-Ellison syndrome (ZES) were prospectively studied. All had controlled acid hypersecretion and were assessed yearly, with a mean follow-up period of 13.8+/-0.6 years (range, 0.1 to 31 years). Annual assessments of possible factors that might affect prognosis or treatment approaches were performed, such as those for tumor size and location; the presence, location, and extent of metastases; and the occurrence of ectopic Cushing's syndrome or another PET syndrome. Deaths were categorized as ZES-related or non-ZES-related and classified into different causes.Thirty-one percent of patients died, all of non-acid-related causes. One half died of a ZES-related cause; they differed from those who died of non-ZES deaths by having a large primary tumor, more frequently a pancreatic tumor; lymph node, liver, or bone metastases; ectopic Cushing's syndrome; or higher gastrin levels. The extent of liver metastases correlated with survival rate. The presence of liver metastases alone only moderately decreased survival time; however, the additional development of bone metastases or ectopic Cushing's syndrome markedly decreased survival rate.In ZES, gastrinoma growth is now the main single determinant of long-term survival, with one half of patients dying a gastrinoma-related death and none an acid-related death. Large primary tumors that are pancreatic in location, the development of liver metastases, (especially if associated with bone metastases or Cushing's syndrome), and the extent of liver metastases are all important prognostic factors. The identification of these factors allows the recognition of subgroups that can be used to tailor antitumor treatment approaches.
Late-breaking abstract: Hypertonic saline in acute bronchiolitis: Randomised controlled trial (RCT) and economic evaluation (the SABRE study)
Authors: Mark L Everard, Daniel Hind, Jennifer V Freeman, Mike Bradburn
Journal: European Respiratory Journal (2014)

DESIGN: Parallel-group, pragmatic RCT in 10 UK hospitals.  METHODS: Infants with acute bronchiolitis - lower respiratory tract infection resulting in airflow obstruction, increase work of breathing and wide spread crepitations on auscultation - requiring oxygen therapy, were eligible. Randomisation, within 4 hrs of admission, was to standard supportive care with oxygen as required, minimal handling and fluid administration as appropriate to the severity of the disease, +/- 6-hourly 3% nebulized hypertonic saline (HS). The hypothesis was that the intervention would result in a 25% reduction in the primary outcome expressed as a hazard ratio (HR), the time to when infants were assessed as being ‘fit for discharge9, defined as, in air with saturations of >92% for 6 hrs. Analysts were blind to allocation.  RESULTS: The trial recruited to target when 158 infants were randomized to HS (141 analysed) and 159 to standard care (149 analysed). There was no difference between the two arms in the time to being declared fit for discharge (HR: 0.95, 95% CI: 0.75-1.20) nor to actual discharge (HR: 0.97, 95% CI: 0.76-1.23). There was no difference in adverse events. One infant developed bradycardia with desaturation associated with HS.  CONCLUSIONS: This study does not support the use of nebulized HS in the treatment of acute bronchiolitis.  REGISTRATION: NCT01469845  FUNDING: National Institute for Health Research.